IDSA, ASM, and PASCV Letter to FDA on LDTs (PDF)

IDSA, ASM and the Pan-American Society for Clinical Virology urge FDA to consider the vital role of lab developed tests in rapidly diagnosing and appropriately treating infectious diseases.

PACCARB Press Release

Recommendations from the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria reflect IDSA input.

IDSA & HIVMA Engage HHS on Drug Pricing and Innovation

IDSA and HIVMA wrote to HHS Secretary Burwell to distinguish efforts to incentivize development of desperately needed new drugs from recent actions to significantly increase the costs of decades old drugs.

IDSA Writes to Senate Aging Committee Ahead of Hearing on Drug Pricing Spikes

IDSA wrote to the Senate Special Committee on Aging ahead of a planned hearing on recent drug price spikes. The IDSA letter distinguished efforts to incentivize development of desperately needed new drugs from recent actions to significantly increase the costs of decades old drugs.

IDSA Leads Stakeholders In Support of R&D Tax Credit for Antibiotics and Rapid Diagnostics

Forty groups representing providers, patients, public health and industry joined a letter – circulated by IDSA – supporting the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act, H.R. 3539.

IDSA Statement: White House Antibiotic Stewardship Forum

At this week’s White House Forum on Stewardship, IDSA President Steve Calderwood, MD, FIDSA said, “Our expertise on diagnosing and treating patients with serious infectious diseases makes us particularly well suited to lead multi-disciplinary institution-level stewardship programs that will improve patient outcomes”

Senators Urged to Support Antibiotic R&D Bill

A bill to establish a new FDA approval pathway for antibacterial drugs to treat life-threatening infections where there exists an unmet medical need has been introduced in the Senate. IDSA members asked to engage their Senators.

IDSA Spearheads Advocacy Effort for AR Funding

IDSA was joined by 56 groups in a letter to congressional appropriators calling for funding to address antimicrobial resistance.